下一代抗體治療：開發產品線及市場 2011-2021

下一代抗體治療：開發產品線及市場 2011-2021 是由出版商Visiongain在2011年11月所出版的。 這份英文市場調查報告書包含185 Pages 價格從美金2642起跳。

簡介

本報告為，關注全球及各地區抗體治療市場，預測2021年止銷售及收益規模，並匯整新技術崛起、治療方式進展、產品世代交替、類別及製藥企業具體趨勢、今後發展挑戰等最新調查資訊及分析，以下列摘要形式闡述。

第1章 實施概要

• 下一代抗體：市場概要
• 本報告內容
• 調查及分析方式

第2章 抗體治療：科學及臨床概要 2011

• 抗體及免疫系統
• 抗體作用機制
• 抗體結構
  • 抗原結合區段
  • 恆定區
• 抗體發現及技術創新概史
• 治療抗體種類
  • 多克隆抗體
  • 單克隆抗體
  • 鼠單克隆抗體
  • 嵌合及人源化單克隆抗體
  • 完全人抗體
  • 抗體結合區段
  • 融合蛋白
• 目前已被許可之單克隆抗體
• 未來可望之下一代抗體

第3章 抗體治療：開發產品線及市場概要 2011-2021

• 抗體治療：市場預測 2011-2021
  • 下一代產品預計市場佔有率將增加
• 抗體治療市場 2011-2021：產品線概要
• 抗體領域前排名企業 2011-2021
• 已開發國家之抗體市場
• 下一代治療抗體技術：SWOT分析

第4章 工程抗體市場 2011-2021

• 工程抗體：市場預測 2011-2021
• 工程抗體：2011連領域概要
• 工程抗體：產品及開發產品線 2011
• 工程抗體：SWOT分析

第5章 抗體藥物共軛市場 2011-2021

• 抗體藥物共軛：市場預測 2011-2021
• 抗體藥物共軛：2011連領域概要
• 抗體藥物共軛：產品及開發產品線 2011
• 抗體藥物共軛：SWOT分析

第6章 雙特異性抗體市場 2011-2021

• 雙特異性抗體：市場預測 2011-2021
• 雙特異性抗體：2011連領域概要
• 雙特異性抗體：產品及開發產品線 2011
• 雙特異性抗體：SWOT分析

第7章 抗體區段市場 2011-2021

• 抗體區段：市場預測 2011-2021
• 抗體區段：2011連領域概要
• 抗體區段：產品及開發產品線 2011
• 抗體區段：SWOT分析

第8章 另類蛋白市場 2011-2021

• 另類蛋白：市場預測 2011-2021
• 另類蛋白：2011連領域概要
• 另類蛋白：產品及開發產品線 2011
• 另類蛋白：SWOT分析

第9章 多克隆抗體市場 2011-2021

• 多克隆抗體：市場預測 2011-2021
• 多克隆抗體：2011連領域概要
• 多克隆抗體：產品及開發產品線 2011
• 多克隆抗體：SWOT分析

第10章 生物仿製藥抗體市場 2011-2021

• 生物仿製藥抗體：市場預測 2011-2021
• 生物仿製藥抗體：2011連領域概要
• 生物仿製藥抗體：產品及開發產品線 2011
• 生物仿製藥抗體：SWOT分析

第11章 訪談調查

• Dr Jason Kantor
• Professor Arne Skerra

第9章 結論

• 持續崛起之新一代抗體產品
• 部分新一代抗體已上市
• 本報告舉出產品外之平台也快於市場受到關注
• 新一代產品將帶給其他抗體多大影響

圖表一覽

企業索引

目錄

Abstract

Report Details

What are the prospects for emerging antibody technologies? Visiongain's report shows you potential revenues to 2021, discussing R&D trends and opportunities.

A new generation of therapeutic antibody is coming. Discover revenue predictions for emerging antibody technologies at total world and submarket levels to 2021. Through our research and analysis we aim to save you time and help in your decisions.

Since the emergence of monoclonal antibodies the technology has not stood still. That industry is about to be transformed again, as new products challenge existing market leaders. Discover emerging trends here.

Which next-generation antibodies will be the most important to the future of antibody therapeutics? Which technologies will be the game-changers in the antibodies industry?

You find many predictions and explanations in this analysis of next-generation antibody technologies. Our study analyses the therapeutic antibodies field by category:

• Engineered antibodies (with enhanced glycosylation and effector functions)
• Antibody-drug conjugates (ADCs)
• Bispecific (and multispecific) antibodies
• Antibody fragments (specifically single-chain variable fragments and single domain antibodies)
• Alternative binding proteins
• Next-generation recombinant polyclonal (and oligoclonal) antibodies
• Biosimilar antibodies.

How will the therapeutic antibody market change? Will biosimilar antibodies disrupt or rejuvenate the market? Our report predicts trends and revenues to 2021 in antibody-based therapeutics.

See activities of Roche, Pfizer, GSK, Kyowa Hakko Kirin, Seattle Genetics, Fresenius, Ablynx, ImmunoGen and other companies. You find developments for cancer treatment and other applications.

Visiongain's report provides data, analysis and opinion to benefit your research, calculations, meetings and presentations. You can find answers now in our work.

Revenue forecasts, market shares, developmental trends, discussions and interviews

In our report you find revenue forecasts, growth rates, market shares, qualitative analyses (incl. SWOT and STEP), opinions from our survey and discussions of technologies and companies. You receive 97 tables and charts and two research interviews.

Advantages of Next-Generation Antibody Therapies: Pipeline and Market 2011-2021 for your work

Our report gives you the following advantages in particular:

• Review R&D for therapeutic antibody technologies, assessing pipeline trends in oncology and other areas of medicine
• Find revenue predictions to 2021 for the overall world market and technological submarkets, seeing revenue prospects
• Assess companies in the antibodies industry, discovering activities and outlooks
• Receive a 2010 revenue breakdown for therapeutic antibody markets in the US, Japan, Germany, France, the UK, Spain, Italy, China and India
• Analyse competition and opportunities from 2011 onwards
• Find out what will stimulate and restrain the industry and market from 2011
• See opportunities and challenges for established and emerging companies
• Read interviews with authorities on the therapeutic antibodies industry.

There, you find a distinctive mix of quantitative and qualitative analyses with independent predictions. We analyse many developments in antibodies, helping you to stay ahead.

Table of Contents

1. Executive Summary

• 1.1 Next-Generation Antibodies: Market Overview
• 1.2 Contents of this Report
• 1.3 Research and Analysis Methods

2. Antibody Therapeutics: Scientific and Clinical Overview, 2011

• 2.1 Antibodies and the Immune System
• 2.2 How Antibodies Work
• 2.3 Structure of Antibodies
  • 2.3.1 The Fab Region
  • 2.3.2 The Fc Region
• 2.4 Brief History of Antibody Discovery and Innovation
• 2.5 Types of Therapeutic Antibody
  • 2.5.1 Polyclonal Antibodies
  • 2.5.2 Monoclonal Antibodies
  • 2.5.3 Murine Monoclonal Antibodies
  • 2.5.4 Chimeric and Humanised Monoclonal Antibodies
  • 2.5.5 Fully Human Monoclonal Antibodies
  • 2.5.6 Fab Fragments
  • 2.5.7 Fusion Proteins
• 2.6 Currently-Approved Monoclonal Antibody Therapies
• 2.7 Potential Next-Generation Antibody Therapeutics

3. Antibody Therapeutics: Pipeline and Market Overview, 2011-2021

• 3.1 Antibody Therapeutics: Market Forecast, 2011-2021
  • 3.3.1 Next-Generation Products will Increase Their Market Share
• 3.2 Antibody Therapeutics Market, 2011-2021: Pipeline Overview
• 3.3 Leading Players in the Antibody Field, 2011-2021
• 3.4 Leading National Antibody Markets
• 3.5 Next-Generation Therapeutic Antibody Technologies: SWOT Analysis
  • 3.5.1 Strengths
  • 3.5.2 Weaknesses
  • 3.5.3 Opportunities
  • 3.5.4 Threats

4. Engineered Antibodies Market, 2011-2021

• 4.1 Engineered Antibodies: Market Forecast, 2011-2021
• 4.2 Engineered Antibodies: Overview of the Field in 2011
  • 4.2.1 The Major Fc Engineering Platforms
  • 4.2.2 New Expression Systems, Purification Systems, and Other Production Improvements
• 4.3 Engineered Antibodies: Products and Pipeline, 2011
  • 4.3.1 Afutuzumab and Other GlycoMAB-Engineered Products (Roche)
  • 4.3.2 KW0761 and Other Potelligent Products (Kyowa Hakko Kirin)
  • 4.3.3 XmAb (Xencor)
  • 4.3.4 MGAH22 and MGA271 (Macrogenics)
  • 4.3.5 AME-133v (Mentrik Biotech)
  • 4.3.6 LFB-R603 (LFB)
• 4.4 Engineered Antibodies: SWOT Analysis
  • 4.4.1 Strengths
  • 4.4.2 Weaknesses
  • 4.4.3 Opportunities
  • 4.4.4 Threats

5. Antibody-Drug Conjugates Market 2011-2021

• 5.1 Antibody-Drug Conjugates: Market Forecast, 2011-2021
• 5.2 Antibody-Drug Conjugates: Overview of the Field in 2011
  • 5.2.1 Existing Antibody-Drug Conjugate Products
• 5.3 Antibody-Drug Conjugates Pipeline, 2011
  • 5.3.1 Trastuzumab DM-1(Roche)
  • 5.3.2 Roche's Other ADC Collaborations (Roche/ Seattle Genetics)
  • 5.3.3 CMC-544 (Pfizer)
  • 5.3.4 IMGN901 (ImmunoGen)
  • 5.3.5 BT-062 (Biotest)
  • 5.3.6 CDX-011 and CDX-014 (Celldex)
  • 5.3.7 BIIB015 (Biogen Idec)
  • 5.3.8 SAR3419 and SAR566658 (Sanofi)
  • 5.3.9 hLL1-Dox and Others (Immunomedics)
  • 5.3.10 MDX-1203 (Bristol-Myers Squibb)
  • 5.3.11 SGN-75 (Seattle Genetics)
  • 5.3.12 AGS-5ME and Others (Astellas/ Agensys/ Seattle Genetics)
  • 5.3.13 BAY 79-4620 and BAY 94-9343 (Bayer Schering/ Seattle Genetics / ImmunoGen)
  • 5.3.14 PSMA ADC (Progenics Pharmaceuticals/ Seattle Genetics)
  • 5.3.15 HuMax ADCs (Genmab/ Seattle Genetics)
  • 5.3.16 Antibody-Radioisotope and Other Immunoconjugate Formats (Various)
• 5.4 Antibody-Drug Conjugates: SWOT Analysis
  • 5.4.1 Strengths
  • 5.4.2 Weaknesses
  • 5.4.3 Opportunities
  • 5.4.4 Threats

6. Bispecific Antibodies Market 2011-2021

• 6.1 Bispecific Antibodies: Market Forecast, 2011-2021
• 6.2 Bispecific Antibodies: Overview of the Field in 2011
• 6.3 Bispecific Antibodies: Pipeline, 2011
  • 6.3.1 Blinatumumab (Micromet)
  • 6.3.2 Other BiTE Products in Development
  • 6.3.3 Rexomun and FBT A05 (Fresenius)
  • 6.3.4 MM-111 (Merrimack)
  • 6.3.5 ImmTAC System (Immunocore)
  • 6.3.6 Tandab (Affimed)
  • 6.3.7 DART Platform (MacroGenics)
  • 6.3.8 CrossMAbs, LUZ-Y and Two-in-One Antibodies (Roche)
  • 6.3.9 Electrostatic Matching (Amgen)
  • 6.3.10 Duobodies (Genmab)
  • 6.3.11 SEED Bodies (Merck Serono)
  • 6.3.12 CovX-Bodies (Pfizer)
  • 6.3.13 TCR-Like Antibodies (ReceptorLogic)
  • 6.3.14 COMBODY (Epigen Biotech)
  • 6.3.15 DVD-Ig (Abbott)
  • 6.3.16 IgG-Like Bispecific (Eli Lilly)
  • 6.3.17 BsAb (Bristol-Myers Squibb)
  • 6.3.18 Hercules (Biogen Idec)
  • 6.3.19 Scorpion (Emergent BioSolutions)
  • 6.3.20 Tribody (Biotecnol)
  • 6.3.21 Dock-and-Lock (ImmunoMedics)
  • 6.3.22 Immunocytokines (ImmunGene)
  • 6.3.23 COBRA (Merus)
• 6.4 Bispecific Antibodies: SWOT Analysis
  • 6.4.1 Strengths
  • 6.4.2 Weaknesses
  • 6.4.3 Opportunities
  • 6.4.4 Threats

7. Antibody Fragments Market 2011-2021

• 7.1 Antibody Fragments: Market Forecast, 2011-2021
• 7.2 Antibody Fragments: Overview of the Field in 2011
• 7.3 Antibody Fragments: Pipeline, 2011
  • 7.3.1 CEP-37247 (Cephalon)
  • 7.3.2 GSK1827771 and Others (GlaxoSmithKline)
  • 7.3.3 Nanobodies (Ablynx)
  • 7.3.4 ESBA105 (ESBATech)
  • 7.3.5 Unibodies (GenMab)
  • 7.3.6 IgNARs (Pfizer)
• 7.4 Antibody Fragments: SWOT Analysis, 2011
  • 7.4.1 Strengths
  • 7.4.2 Weaknesses
  • 7.4.3 Opportunities
  • 7.4.4 Threats

8. Alternative Binding Proteins Market 2011-2021

• 8.1 Alternative Binding Proteins: Market Forecast, 2011-2021
• 8.2 Alternative Binding Proteins: Overview of the Field in 2011
• 8.3 Alternative Binding Proteins: Pipeline, 2011
  • 8.3.1 Adnectins (Adnexus)
  • 8.3.2 DARPins (Molecular Partners)
  • 8.3.3 Anticalins (Pieris)
  • 8.3.4 Affibodies (Affibody)
  • 8.3.5 Avimers (Amgen)
  • 8.3.6 Transbodies (Pfizer)
  • 8.3.7 Fynomers (Covagen)
  • 8.3.8 Affilins (Scil Proteins)
  • 8.3.9 Evibodies (Arana Therapeutics)
  • 8.3.10 C-Type Lectins (Borean Pharma)
• 8.4 Alternative Binding Proteins: SWOT Analysis, 2011
  • 8.4.1 Strengths
  • 8.4.2 Weaknesses
  • 8.4.3 Opportunities
  • 8.4.4 Threats

9. Polyclonal Antibodies Market 2011-2021

• 9.1 Polyclonal Antibodies: Market Forecast, 2011-2021
• 9.2 Polyclonal Antibodies: Overview of the Field in 2011
• 9.3 Polyclonal Antibodies: Pipeline, 2011
  • 9.3.1 Symphogen Polyclonal Antibodies Platform
  • 9.3.2 Merus HYDRA Polyclonal Antibodies Platform
• 9.4 Polyclonal Antibodies: SWOT Analysis, 2011
  • 9.4.1 Strengths
  • 9.4.2 Weaknesses
  • 9.4.3 Opportunities
  • 9.4.4 Threats

10. Biosimilar Antibodies Market 2011-2021

• 10.1 Biosimilar Antibodies: Market Forecast, 2011-2021
• 10.2 Overview of Biosimilar Antibodies
• 10.3 Biosimilar Antibodies: Prospects in 2011
  • 10.3.1 Biosimilar Antibody Regulatory Guidance in Europe
• 10.4 Biosimilar Antibodies: SWOT Analysis, 2011
  • 10.4.1 Strengths
  • 10.4.2 Weaknesses
  • 10.4.3 Opportunities
  • 10.4.4 Threats

11. Research Interviews

• 11.1 Interview with Dr Jason Kantor
  • 11.1.1 On Progress in Antibody-Drug Conjugates
  • 11.1.2 On Pharma Strategies for Next-Generation Antibody Technologies
  • 11.1.3 On Competition between Next-Generation Sectors
  • 11.1.4 On Engineered Antibodies
  • 11.1.5 On Biosimilars
  • 11.1.6 On Next-Generation Antibodies and Personalised Medicine
• 11.2 Interview with Professor Arne Skerra
  • 11.2.1 On the Benefits of Non-Immunoglobulin Binding Proteins
  • 11.2.2 On the Alternative Binding Proteins Pipeline
  • 11.2.3 On Big Pharma Buyouts and Business Drivers in the Sector
  • 11.2.4 On Antibody Fragments Compared to Alternative Binding Proteins
  • 11.2.5 On Pieris' Lipocalin Scaffolds and Lead Candidate Angiocal
  • 11.2.6 On Immunogenicity and Plasma Half-Life

12. Conclusions

• 12.1 A New Generation of Antibody Products is Emerging
• 12.2 Some Next-Generation Antibodies are Already Here
• 12.3 Other Innovative Platforms are about to Achieve Market Breakthrough
• 12.4 Next-Generation Products Will Have Important Consequences for Other Antibodies

List of Tables

• Table 2.1 Timeline of Salient Innovations and Market Launches in the Therapeutic Antibodies Field
• Table 2.2 Types of Therapeutic Monoclonal Antibody Product, 2011
• Table 2.3 Murine Antibody Products on the Market, 2011
• Table 2.4 Chimeric Antibody Products on the Market, 2011
• Table 2.5 Humanised Antibody Products on the Market, 2011
• Table 2.6 Fully-Human Antibody Products on the Market, 2011
• Table 2.7 Fab Fragment Antibody Products on the Market, 2011
• Table 2.8 Fusion Protein Products on the Market, 2011
• Table 2.9 Monoclonal Antibodies Approved in the US, 2011
• Table 2.10 Monoclonal Antibodies Approved Outside US Only
• Table 2.11 Different Categories of Next-Generation Antibodies Considered in this Report
• Table 2.12 Next-Generation Products Already on the Market, 2011
• Table 3.1 Antibodies Market Breakdown: Revenues ($m), Market Shares (%), 2010
• Table 3.2 Next-Generation Antibodies Market Breakdown: Revenues ($m), Market Shares (%), 2010
• Table 3.3 Therapeutic Antibodies Market: Revenues ($bn), AGR (%), CAGR (%), 2010-2015
• Table 3.4 Therapeutic Antibodies Market: Revenues ($bn), AGR (%), CAGR (%), 2016-2021
• Table 3.5 Next-Generation Therapeutic Antibodies Market: Revenues ($m), AGR (%), CAGR (%), 2010-2015
• Table 3.6 Next-Generation Therapeutic Antibodies Market: Revenues ($m), AGR (%), CAGR (%), 2016-2021
• Table 3.7 Antibodies Market Breakdown: Revenues ($m), Market Shares (%), 2015
• Table 3.8 Antibodies Market Breakdown: Revenues ($m), Market Shares (%), 2021
• Table 3.9 Next-Generation Antibodies Market, Breakdown by Categories: Revenues ($m), AGR (%), CAGR (%), Shares of Next-Generation Antibodies Market (%), Shares of Overall Antibodies Market (%), 2010-2015
• Table 3.10 Next-Generation Antibodies Market Breakdown: Revenues ($m), Market Shares (%), 2015
• Table 3.11 Next-Generation Antibodies Market, Breakdown by Categories: Revenues ($m), AGR (%), CAGR (%), Shares of Next-Generation Antibodies Market (%), Shares of Overall Antibodies Market (%), 2016-2021
• Table 3.12 Next-Generation Antibodies Market Breakdown: Revenues ($m), Market Shares (%), 2021
• Table 3.13 Next-Generation Antibody Therapeutics: Leading Pipeline Contenders, 2011
• Table 3.14 Top 10 Next-Generation Antibody Therapeutic Technology Platforms, 2011
• Table 3.15 Antibodies Market, Breakdown by National Market: Revenues ($bn), Market Shares (%), 2010
• Table 3.16 Strengths and Weaknesses of the Next-Generation Antibodies Sector, 2011
• Table 3.17 Opportunities and Threats in the Next-Generation Antibodies Sector, 2011
• Table 4.1 Engineered Antibodies Market: Revenues ($m), AGR (%), CAGR (%), Share of Next-Generation Antibodies Market (%), Share of Overall Antibodies Market (%), 2010-2015
• Table 4.2 Engineered Antibodies Market: Revenues ($m), AGR (%), CAGR (%), Share of Next-Generation Antibodies Market (%), Share of Overall Antibodies Market (%), 2016-2021
• Table 4.3 Engineered Antibodies Market: Clinical Pipeline, 2011
• Table 4.4 Engineered Antibodies Market: Preclinical Pipeline, 2011
• Table 4.5 Engineered Antibody Products Based on GlycArt Technology, 2011
• Table 4.6 Engineered Antibody Products Based on POTelligent Technology, 2011
• Table 4.7 Engineered Antibody Products Based on XmAb Technology, 2011
• Table 4.8 Strengths and Weaknesses of the Engineered Antibodies Sector, 2011
• Table 5.1 Antibody-Drug Conjugates Market: Revenues ($m), AGR (%), CAGR (%), Share of Next-Generation Antibodies Market (%), Share of Overall Antibodies Market (%), 2010-2015
• Table 5.2 Antibody-Drug Conjugates Market: Revenues ($m), AGR (%), CAGR (%), Share of Next-Generation Antibodies Market (%), Share of Overall Antibodies Market (%), 2016-2021
• Table 5.3 Antibody-Drug Conjugates Market: Clinical Pipeline, 2011
• Table 5.4 Antibody-Drug Conjugates Market: Preclinical Pipeline, 2011
• Table 5.5 Immunogen ADC Collaborations, 2011
• Table 5.6 Seattle Genetics ADC Collaborations, 2011
• Table 5.7 Antibody-Radioisotope and Other Immunconjugate Formats: Clinical Pipeline, 2011
• Table 5.8 Strengths and Weaknesses of the Antibody-Drug Conjugates Sector, 2011
• Table 5.9 Opportunities and Threats in the Antibody-Drug Conjugates Sector, 2011
• Table 6.1 Bispecific Antibodies Market: Revenues ($m), AGR (%), CAGR (%), Share of Next-Generation Antibodies Market (%), Share of Overall Antibodies Market (%), 2010-2015
• Table 6.2 Bispecific Antibodies Market: Revenues ($m), AGR (%), CAGR (%), Share of Next-Generation Antibodies Market (%), Share of Overall Antibodies Market (%), 2016-2021
• Table 6.3 Bispecific Antibodies Market: Clinical Pipeline, 2011
• Table 6.4 Bispecific Antibodies Market: Preclinical Pipeline, 2011
• Table 6.5 Strengths and Weaknesses of the Bispecific Antibodies Sector, 2011
• Table 6.6 Opportunities and Threats in the Bispecific Antibodies Sector, 2011
• Table 7.1 Antibody Fragments Market: Revenues ($m), AGR (%), CAGR (%), Share of Next-Generation Antibodies Market (%), Share of Overall Antibodies Market (%), 2010-2015
• Table 7.2 Antibody Fragments Market: Revenues ($m), AGR (%), CAGR (%), Share of Next-Generation Antibodies Market (%), Share of Overall Antibodies Market (%), 2016-2021
• Table 7.3 Antibody Fragments: Clinical Pipeline, 2011
• Table 7.4 Antibody Fragments: Preclinical Pipeline, 2011
• Table 7.5 Strengths and Weaknesses of the Antibody Fragments Sector, 2011
• Table 7.6 Opportunities and Threats in the Antibody Fragments Sector, 2011
• Table 8.1 Alternative Binding Proteins Market: Revenues ($m), AGR (%), CAGR (%), Share of Next-Generation Antibodies Market (%), Share of Overall Antibodies Market (%), 2016-2021
• Table 8.2 Alternative Binding Proteins: Clinical Pipeline, 2011
• Table 8.3 Alternative Binding Proteins: Preclinical Pipeline, 2011
• Table 8.4 Strengths and Weaknesses of the Alternative Binding Proteins Sector, 2011
• Table 8.5 Opportunities and Threats in the Alternative Binding Proteins Sector, 2011
• Table 9.1 Polyclonal Antibodies Market: Revenues ($m), AGR (%), CAGR (%), Share of Next-Generation Antibodies Market (%), Share of Overall Antibodies Market (%), 2010-2015
• Table 9.2 Polyclonal Antibodies Market: Revenues ($m), AGR (%), CAGR (%), Share of Next-Generation Antibodies Market (%), Share of Overall Antibodies Market (%), 2016-2021
• Table 9.3 Polyclonal Antibodies: Clinical Pipeline, 2011
• Table 9.4 Polyclonal Antibodies: Preclinical Pipeline, 2011
• Table 9.5 Strengths and Weaknesses of the Polyclonal Antibodies Sector, 2011
• Table 9.6 Opportunities and Threats in the Polyclonal Antibodies Sector, 2011
• Table 10.1 Biosimilar Antibodies Market: Revenues ($m), AGR (%), CAGR (%), Share of Next-Generation Antibodies Market (%), Share of Overall Antibodies Market (%), 2010-2015
• Table 10.2 Biosimilar Antibodies Market: Revenues ($m), AGR (%), CAGR (%), Share of Next-Generation Antibodies Market (%), Share of Overall Antibodies Market (%), 2016-2021
• Table 10.3 Strengths and Weaknesses of the Biosimilar Antibodies Sector, 2011
• Table 10.4 Opportunities and Threats for the Biosimilar Antibodies Sector, 2011

List of Figures

• Figure 3.1 Antibodies Market Breakdown: Revenues ($m), Market Shares (%), 2010
• Figure 3.2 Next-Generation Antibodies Market Breakdown: Revenues ($m), Market Shares (%), 2010
• Figure 3.3 Therapeutic Antibodies Market: Revenues ($bn), 2010-2015
• Figure 3.4 Therapeutic Antibodies Market: Revenues ($bn), 2016-2021
• Figure 3.5 Next-Generation Therapeutic Antibodies Market: Revenues ($m), 2010-2015
• Figure 3.6 Next-Generation Therapeutic Antibodies Market: Revenues ($m), 2016-2021
• Figure 3.7 Antibodies Market Breakdown, Revenues ($m), Market Shares (%), 2015
• Figure 3.8 Antibodies Market Breakdown: Revenues ($m), Market Shares (%), 2021
• Figure 3.9 Next-Generation Antibodies Market, Breakdown by Categories: Revenues ($m), 2010-2015
• Figure 3.10 Next-Generation Antibodies Market Breakdown: Revenues ($m), Market Shares (%), 2015
• Figure 3.11 Next-Generation Antibodies Market, Breakdown by Categories: Revenues ($m), 2016-2021
• Figure 3.12 Next-Generation Antibodies Market Breakdown: Revenues ($m), Market Shares (%), 2021
• Figure 3.13 Antibodies Market, Breakdown by National Market: Revenues ($bn), Market Shares (%), 2010
• Figure 4.1 Engineered Antibodies Market: Revenues ($m), 2010-2015
• Figure 4.2 Engineered Antibodies Market: Revenues ($m), 2016-2021
• Figure 5.1 Antibody-Drug Conjugates Market: Revenues ($m), 2010-2015
• Figure 5.2 Antibody-Drug Conjugates Market: Revenues ($m), 2016-2021
• Figure 6.1 Bispecific Antibodies Market: Revenues ($m), 2010-2015
• Figure 6.2 Bispecific Antibodies Market: Revenues ($m), 2016-2021
• Figure 7.1 Antibody Fragments Market: Revenues ($m), 2015-2021
• Figure 8.1 Alternative Binding Proteins Market: Revenues ($m), 2016-2021
• Figure 9.1 Polyclonal Antibodies Market: Revenues ($m), 2015-2021
• Figure 10.1 Biosimilar Antibodies Market: Revenues ($m), 2010-2015
• Figure 10.2 Biosimilar Antibodies Market: Revenues ($m), 2016-2021

Companies Listed

• Abbott Laboratories
• Ablynx
• Alexion Pharmaceuticals
• Amgen
• Arana Therapeutics
• Astellas Pharma
• AstraZeneca
• Affibody
• Affimed Therapeutics
• American Society of Clinical Oncology
• Applied Molecular Evolution
• Bayer Healthcare
• Bayer Schering
• BayTech Venture Capital
• BioCon
• Biogen Idec
• Biolex Therapeutics
• BioTech Pharma
• Biotecnol
• Biotest Pharmaceuticals
• BioWa
• Boehringer Ingelheim
• Borean Pharma
• Bradmer Pharmaceuticals
• Bristol-Myers Squibb
• Cancer Research Technology
• Celldex Therapeutics
• Celltech
• Cell Therapeutics
• Cephalon
• Cevec Pharmaceuticals
• Chengdu Hoist Biotech
• Corixa Corporation
• Crucell
• Covagen
• Daiichi Sankyo
• Delenex Therapeutics
• Diversys
• Domantis
• Dresden University of Technology
• Dr. Reddy's Laboratories
• Elan Pharmaceuticals
• Eli Lilly
• Emergent BioSolutions
• Epigen Biotech
• ESBATech
• EuroFarma
• European Medicines Agency (EMEA/EMA)
• Food and Drug Administration (US FDA)
• Forbion Capital
• Fresenius
• Genentech
• Genmab
• Gilde Healthcare Partners
• GlaxoSmithKline (GSK)
• Global Life Science Ventures
• GlycArt
• GTV Biotherapeutics
• Haptogen
• Human Genome Sciences
• ImmunGene
• Immunocore
• ImmunoGen
• Immunomedics
• Isu Abxis
• Johnson & Johnson
• Kyowa Hakko Kirin
• Laboratoires Francais de Fractionnement et des Biotechnologies (LFB)
• Ludwig Institute for Cancer Research
• Mabgene
• Macrogenics
• Medarex
• MedImmune
• Meiji Seika Pharma
• Memorial Sloan-Kettering Cancer Center
• Mentrik Biotech
• Merck & Co.
• Merck KGaA
• Merck Serono
• Merrimack Pharmaceuticals
• Merus Biopharmaceuticals
• Micromet
• Molecular Partners
• MorphoSys
• Novartis
• OrbiMed Advisors
• Oslo University Hospital
• Oxford BioMedica
• Peptech Corporation
• Percivia
• Pfizer
• Pharming Healthcare
• Pieris
• Progenics Pharmaceuticals
• RBC Capital Markets
• ReceptorLogic
• Regeneron Pharmaceuticals
• Roche
• Roslin Institute
• Sanofi
• Scil Proteins
• SeaGen Secure
• Seattle Genetics
• Soroka University Medical Centre
• Spectrum Pharmaceuticals
• Sutro Biopharma
• Swiss Federal Institute of Technology
• Symphogen
• Takeda Pharmaceutical Company
• Technical University of Munich
• Teva Pharmaceutical Industries
• Tufts Centre for Drug Discovery
• UCB
• University of Aberdeen
• University of Oxford
• Viragen
• Wacker Biosolutions
• Wyeth
• Xencor

Press Release

下一代治療用抗體之收益，預計於2015年達到23億美金

相關商品

抗體和免疫相關市場調查報告書

白血病、蛋白質激酶抑制劑、抗體：藥劑開發策略分析
Triple Analysis: Leukemia, Protein Kinase Inhibitors and Antibodies
價格 : US $ 5175
出版日期 : 2012年05月

淋巴癌、蛋白質激酶抑制劑、抗體：藥劑開發策略分析
Triple Analysis: Lymphoma, Protein Kinase Inhibitors and Antibodies
價格 : US $ 5175
出版日期 : 2012年05月

肺癌，淋巴瘤，Protein Kinase抗化劑:藥物開發策略分析
Triple Analysis: Lung Cancer, Lymphoma and Protein Kinase Inhibitors
價格 : US $ 5175
出版日期 : 2012年05月

Visiongain發行的生物科技相關市場調查報告書

生物性骨材:全球市場展望 2012-2022年

Orthobiologics: Global Market Prospects 2012-2022

價格 : US $ 2642

出版日期 : 2012年03月

生物製藥的全球市場:2012-2022年

World Biological Drugs Market 2012-2022

價格 : US $ 2642

出版日期 : 2012年02月

全球細胞化驗分析市場展望:2012-2022年

Cell-Based Assays: World Market Prospects 2012-2022

價格 : US $ 2642

出版日期 : 2012年01月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!